Clinical Trials Directory
We are doing this study to find out if an experimental drug called Actinium-225 rosopatamab tetraxetan (the study drug) is a safe and effective option for patients with castration-resistant prostate cancer (CRPC).
The treatment will last for 12 months. People in the study will get shots of a medicine called omalizumab. Some will get the shots every month, and others will get them every two weeks. At each visit, they will answer questions on forms. Blood will be taken at the first visit and the last visit.
People who join this study will answer surveys by phone, online, or in person. They will also give regular blood samples. Some people will be asked to do extra tests that check how their body handles sugar, measure special biomarkers, and look at how well their blood vessels work. Participants will be followed for two years. The study will also use information from their electronic health records over time.
This study lasts about 14 weeks and includes 8 planned visits to the clinic. If you qualify during the first part of the study, you will be randomly placed into one of three groups. Each person in the study will get two doses of a medicine called CRD-4730 and one dose that does not contain any medicine, called a placebo. The order of these doses is chosen by chance. Each dose is given over two weeks. You will go to the clinic on the first and last day of each dose. Between each dose, there is a two-week break when you do not take any medicine. During your visits, doctors may do check-ups like physical exams, blood and urine tests, heart tests, stress tests, and more. At home, you will use a device to check your heart every day and write down your results. You will also follow instructions for taking the medicine and keep a diary to record each time you take it.
We are doing this study to better understand how breast cancer treatment can affect the heart. In particular, we want to know if treatment with near complete estrogen deprivation (NCED) therapy has an impact on heart function.
We are doing this study to find out if using ice with or without compression during chemotherapy can prevent neuropathy for patients being treated for gynecologic cancer.
We are doing this study to collect cerebrospinal fluid (CSF) samples from people with cancer that has spread to the leptomeninges (the inner membranes that cover the brain and spinal cord). These CSF samples will be used in laboratory research projects to identify substances called biomarkers. Biomarker testing is a way to look for genes, proteins, and other substances (tumor markers) that can provide information about cancer. Information from these CSF samples may help us learn about new methods to treat metastatic disease to the leptomeninges.